Condition: Asthma
Interventions: Drug: Benralizumab; Other: Placebo
Sponsor: AstraZeneca
Not yet recruiting – verified August 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Asthma
Interventions: Drug: Benralizumab; Other: Placebo
Sponsor: AstraZeneca
Not yet recruiting – verified August 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Conditions: Chronic Obstructive Pulmonary Disease; Bronchial Asthma; Interstitial Lung Disease
Interventions: Device: multiple breath washout test (MBW); Device: impulse oscillometry (IOS); Device: body plethysmography (BP); Device: quantitative computed tomography (qCT)
Sponsor: Universitätsmedizin Mannheim
Recruiting – verified July 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Reslizumab improves asthma control, symptoms, lung function
Healio “Intravenous reslizumab [Cinqair, Teva Respiratory] 3.0 mg/kg provided improvements in lung function, asthma symptoms, and quality of life for patients with inadequately controlled asthma and elevated blood eosinophils (? 400 cells/µL) that were … |
View full post on asthma – Google News
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg; Drug: Fluticasone furoate 100 mcg + Vilanterol 25 mcg; Drug: Umeclidinium 62.5 mcg; Device: Placebo ELLIPTA inahler; Drug: Albuterol/Salbutamol
Sponsor: GlaxoSmithKline
Not yet recruiting – verified April 2016
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Vitamin D and Lung Function Decline in Adults With Asthma: The HUNT Study.
Am J Epidemiol. 2016 Mar 18;
Authors: Brumpton BM, Langhammer A, Henriksen AH, Camargo CA, Chen Y, Romundstad PR, Mai XM
Abstract
We investigated whether low 25-hydroxyvitamin D (25(OH)D) levels were associated with more lung function decline in adults with asthma and whether this association was modified by smoking status or inhaled corticosteroid (ICS) use. We analyzed data on 395 adults with asthma from the Nord-Trøndelag Health Study (1995-2008), Norway. Plasma 25(OH)D and lung function were measured at baseline, and lung function measurements were repeated at follow-up, approximately 11 years later. Linear regression was used to estimate lung function decline. Participants with low 25(OH)D (<50 nmol/L) had more decline in lung function measurements for forced expiratory volume in 1 second (FEV1) (388 mL), forced vital capacity (298 mL), and the FEV1/forced vital capacity ratio (3.7%) over the follow-up, compared with those with high 25(OH)D (?50 nmol/L) who declined 314 mL, 246 mL, and 3.0%, respectively (P = 0.08, 0.30, and 0.23, respectively). The associations were stronger in never smokers and non-ICS users. In never smokers, low 25(OH)D levels were associated with more decline in FEV1 (445 vs. 222 mL) (P = 0.01). In non-ICS users, low 25(OH)D levels were associated with more decline in FEV1 (467 vs. 320 mL) (P = 0.02). Low serum 25(OH)D levels were weakly associated with more lung function decline in adults with asthma, and stronger associations were observed in never smokers and non-ICS users.
PMID: 26994061 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Newswise (press release) |
African Ancestry Predicts Lung Function in Minority Youth with Asthma
Newswise (press release) The study, “Air Pollution and Lung Function in Minority Youth with Asthma in the GALA II & SAGE II Studies,” which appeared in the journal's online edition, is believed to be the first to look at interaction between exposure to pollutants and genetic … |
View full post on asthma – Google News
Medical Xpress |
Obesity worsens lung function for kids, young people with asthma
Medical Xpress Robert Strunk, MD, examines LeBron Reed, a patient with asthma. Strunk, of Washington University School of Medicine in St. Louis, led a study showing the importance of children with asthma maintaining healthy weight as they grow into young adults … |
View full post on asthma – Google News
Olodaterol improves lung function in patients with asthma
Healio “The results of this study add support to the growing evidence base that olodaterol delivered by Respimat (Boehringer Ingelheim) [once-daily] provides effective 24-hour bronchodilation in both COPD and asthma,” Kai-Michael Beeh, MD, founder of Insaf … |
View full post on asthma – Google News
Related Articles |
Ambient air pollution, lung function, and airway responsiveness in asthmatic children.
J Allergy Clin Immunol. 2015 Jun 29;
Authors: Ierodiakonou D, Zanobetti A, Coull BA, Melly S, Postma DS, Boezen HM, Vonk JM, Williams PV, Shapiro GG, McKone EF, Hallstrand TS, Koenig JQ, Schildcrout JS, Lumley T, Fuhlbrigge AN, Koutrakis P, Schwartz J, Weiss ST, Gold DR, Childhood Asthma Management Program Research Group
Abstract
BACKGROUND: Although ambient air pollution has been linked to reduced lung function in healthy children, longitudinal analyses of pollution effects in asthmatic patients are lacking.
OBJECTIVE: We sought to investigate pollution effects in a longitudinal asthma study and effect modification by controller medications.
METHODS: We examined associations of lung function and methacholine responsiveness (PC20) with ozone, carbon monoxide (CO), nitrogen dioxide, and sulfur dioxide concentrations in 1003 asthmatic children participating in a 4-year clinical trial. We further investigated whether budesonide and nedocromil modified pollution effects. Daily pollutant concentrations were linked to ZIP/postal code of residence. Linear mixed models tested associations of within-subject pollutant concentrations with FEV1 and forced vital capacity (FVC) percent predicted, FEV1/FVC ratio, and PC20, adjusting for seasonality and confounders.
RESULTS: Same-day and 1-week average CO concentrations were negatively associated with postbronchodilator percent predicted FEV1 (change per interquartile range, -0.33 [95% CI, -0.49 to -0.16] and -0.41 [95% CI, -0.62 to -0.21], respectively) and FVC (-0.19 [95% CI, -0.25 to -0.07] and -0.25 [95% CI, -0.43 to -0.07], respectively). Longer-term 4-month CO averages were negatively associated with prebronchodilator percent predicted FEV1 and FVC (-0.36 [95% CI, -0.62 to -0.10] and -0.21 [95% CI, -0.42 to -0.01], respectively). Four-month averaged CO and ozone concentrations were negatively associated with FEV1/FVC ratio (P < .05). Increased 4-month average nitrogen dioxide concentrations were associated with reduced postbronchodilator FEV1 and FVC percent predicted. Long-term exposures to sulfur dioxide were associated with reduced PC20 (percent change per interquartile range, -6% [95% CI, -11% to -1.5%]). Treatment augmented the negative short-term CO effect on PC20.
CONCLUSIONS: Air pollution adversely influences lung function and PC20 in asthmatic children. Treatment with controller medications might not protect but rather worsens the effects of CO on PC20. This clinical trial design evaluates modification of pollution effects by treatment without confounding by indication.
PMID: 26187234 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Table 2. Effect of bariatric surgery on lung function
Medscape Background The pathogenesis of asthma in obese subjects is poorly understood and has been described as a specific phenotype in these patients. Weight loss improves asthma control and lung function. Whether this improvement is the result of better … |
View full post on asthma – Google News